Symposium:
5. New Insights into the Microbiology and Epidemiology of Multidrug-Resistant Gram-Negative Bacteria
Wednesday, October 2, 2013: 1:30 PM-3:30 PM
Room: The Moscone Center: 134 (Hall E)
Co-organized with the European Society of Clinical Microbiology and Infectious Diseases

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the epidemiology of emerging carbapenemases, including New Delhi metallo-β-lactamase (NDM) and OXAs, inside and outside of healthcare settings worldwide
  • recognize the effect of natural environmental factors on the spread of antibiotic-resistance in Gram-negative bacteria
  • list advantages and disadvantages of different laboratory methods for the detection of carbapanemase-producing bacteria in clinical and surveillance specimens
  • discuss the clinical consequences and infection control implications of the increasing incidence of community infections due to extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae

Target Audience: scientists, researchers, public health practitioners, pharmacists, nurses, microbiologists, members-in-training, lab personnel, investigators, infectious diseases physicians, infectious diseases pediatricians, infection preventionists, hospital epidemiologists, hospital administrators, HIV specialists, HIV clinicians, health care workers, fellows, epidemiologists, clinicians, academicians

Tracks: Pediatric ID, Investigative ID, Global ID, Epidemiology and Infection Control, Adult ID

Moderators:  Trish M. Perl, MD, MSc, FIDSA, FSHEA, Johns Hopkins Medical Institutions and Jesus Rodriguez-Bano, MD, Hospital Universitario Virgen Macarena

CME Credits: Maximum of 2 hours of AMA PRA Category 1 CreditTM

ACPE Credits: No CPE credit is offered for this session.

ACPE Number:

Disclosures:

T. M. Perl, None

J. Rodriguez-Bano, Merck: Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium
AstraZeneca: Speaker's Bureau, Speaker honorarium

D. L. Paterson, Merck: Consultant and Speaker's Bureau, Consulting fee and Speaker honorarium
AstraZeneca: Consultant and Speaker's Bureau, Consulting fee and Speaker honorarium
Pfizer: Consultant and Speaker's Bureau, Consulting fee and Speaker honorarium

P. Hawkey, None

J. Rodriguez-Bano, Merck: Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium
AstraZeneca: Speaker's Bureau, Speaker honorarium

S. Jenkins, BioFire Diagnostics: Scientific Advisor, Consulting fee

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.